Pulmonary nocardiosis (PN) is an infrequent and severe infection due to *Nocardia* spp., microorganisms that may behave both as opportunists and as primary pathogens. The aim of this study and review was to evaluate the clinical features, evolution and prognostic factors of PN.

The study group comprised 10 consecutive patients with pulmonary nocardiosis acquired in a community setting, diagnosed and followed in a tertiary teaching hospital. Chronic obstructive pulmonary disease (COPD), neoplastic disease and human immunodeficiency virus (HIV) infection were the most frequent predisposing factors. Four patients were receiving corticosteroid treatment. Clinical course was chronic and diagnosis was delayed 3 weeks or more in seven of the patients. Lobar or multilobar condensation was the most frequent radiographic pattern. Antimicrobial susceptibility testing showed: 100% sensitivity for amikacin; 83% for imipenem; 71% for cefotaxime; and 71% for trimethoprim-sulphamethoxazole. The disease remained localized in the lung in five cases, with a trend toward chronicity in one with bronchiectasis. In the other five, the disease disseminated, affecting subcutaneous tissue, the central nervous system and the kidney. Three patients died, one with disseminated disease and two who were receiving corticosteroid therapy.

The following conclusions were reached: 1) pulmonary nocardiosis is difficult to diagnose, diagnosis is frequently delayed and a high level of suspicion is, thus, required in patients with underlying diseases or chronic corticosteroid therapy; 2) there is frequent dissemination and high mortality; and 3) antimicrobial combinations with proven synergy, such as imipenem and amikacin, are recommended for initial therapy.

Experience of pulmonary nocardiosis in the medical literature is limited to case reports, with few series, the latter also including extrapulmonary nocardiosis. The aim of the present review was to evaluate the clinical features, evolution and prognostic factors in a series of 10 cases of nocardiosis with pulmonary involvement.
and, eventually, death and cause of death. The extent of disease was divided into two categories: localized or disseminated. Localized infection was confined to one organ. Disseminated nocardiosis was defined as infection in two noncontiguous organs or in the central nervous system [5].

Results

Characteristics and clinical features of the patients

From January 1989 to May 1994, 18 patients were diagnosed with nocardial infection. Eight patients were excluded because of nonpulmonary disease (five in subcutaneous tissue, two with brain abscess associated with subcutaneous tissue infection, and one with renal involvement). Finally, 10 patients were included (seven males and three females), with a mean age of 53 yrs (range: 18–73 yrs). Characteristics of the patients, with demographic data, concurrent illnesses, prior treatment and analytical results, are detailed in table 1. The following diseases were associated in 8 of the 10 patients: chronic obstructive pulmonary disease (3); human immunodeficiency virus (HIV) infection (2); neoplastic disease (2); alcoholism (1); and bronchiectasis (1). Three of the patients were receiving corticosteroid therapy, and one patient was receiving corticosteroid and immunosuppressive therapy (cisplatin + 5-fluorouracil). HIV-positive patients were staged according to the Centers for Disease Control and Prevention (CDC) 1986 classification (patient No. 4: group IV with CD4+ T-lymphocyte count of 12 cells·mm⁻³; patient No. 8: group II with CD4+ of 756 cells·mm⁻³).

The clinical manifestations in the 10 patients were: cough (10); purulent expectoration (7); and fever (7). In general, the clinical course was chronic, with a duration of symptoms before diagnosis of 3 weeks or more in 7 of the 10 (range 1 week to 3 months). Absolute and differential white blood cell (WBC) counts and erythrocyte sedimentation rate (ESR) at diagnosis are presented in table 1.

Radiographic patterns

The radiographic picture of the 10 patients included several manifestations: lobar or multilobar consolidation (7); solitary masses (2); and reticulonodular infiltrate (1). Pleural effusion occurred in three of the 10 patients, and cavitary lesion in three. The upper lobes were involved in 70%. Unilateral disease was noted in six patients and bilateral in four. The progression of radiographic abnormalities was slow.

Microbiological identification

Microbiological diagnosis was made in all patients by isolation of Nocardia spp. from respiratory samples (table 2): sputum cultures in 9 out of 10; bronchoalveolar lavage samples in 2; pleural fluid cultures in 2; bronchial washings in 2; and biopsies in 2. Nocardia spp. were isolated from blood in 2 patients (1 HIV-positive; 1 COPD). Nocardia asteroides was the most frequently isolated species, followed by Nocardia brasiliensis. Of the 10 patients, 9 were treated with trimethoprim-sulphamethoxazole (TMP-SMX) as part of their initial therapy. All patients were treated with aminoglycosides in addition to TMP-SMX; all patients were treated with quinolones (ciprofloxacin, netilmicin, amoxicillin-clavulanic acid) as part of their initial therapy. All patients were treated with corticosteroids for immunosuppression.

Table 1. – Clinical characteristics and analytical results

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age yrs</th>
<th>Sex</th>
<th>Concurrent illness</th>
<th>Steroids</th>
<th>WBC ×10^9·L⁻¹</th>
<th>Differential count %</th>
<th>ESR mm·h⁻¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>71</td>
<td>M</td>
<td>Vesicular carcinoma</td>
<td>Prednisone 10 mg·day⁻¹ for 9 months</td>
<td>17.0</td>
<td>75</td>
<td>18</td>
</tr>
<tr>
<td>2</td>
<td>65</td>
<td>M</td>
<td>Bronchogenic carcinoma</td>
<td>Dexamethasone 8 mg·day⁻¹ for 60 days</td>
<td>7.8</td>
<td>81</td>
<td>12</td>
</tr>
<tr>
<td>3</td>
<td>18</td>
<td>F</td>
<td>-</td>
<td>-</td>
<td>9.9</td>
<td>73</td>
<td>17</td>
</tr>
<tr>
<td>4</td>
<td>20</td>
<td>M</td>
<td>HIV infection</td>
<td>-</td>
<td>4.4</td>
<td>77</td>
<td>10</td>
</tr>
<tr>
<td>5</td>
<td>73</td>
<td>M</td>
<td>COPD</td>
<td>-</td>
<td>29.0</td>
<td>94</td>
<td>1</td>
</tr>
<tr>
<td>6</td>
<td>56</td>
<td>M</td>
<td>Alcoholism</td>
<td>-</td>
<td>10.7</td>
<td>88</td>
<td>5</td>
</tr>
<tr>
<td>7</td>
<td>64</td>
<td>M</td>
<td>COPD, bronchiectasis</td>
<td>-</td>
<td>8.6</td>
<td>58</td>
<td>26</td>
</tr>
<tr>
<td>8</td>
<td>33</td>
<td>M</td>
<td>HIV infection</td>
<td>Prednisone 40 mg·day⁻¹ for 15 days</td>
<td>7.7</td>
<td>78</td>
<td>16</td>
</tr>
<tr>
<td>9</td>
<td>50</td>
<td>F</td>
<td>-</td>
<td>3.9</td>
<td>68</td>
<td>36</td>
<td>20</td>
</tr>
<tr>
<td>10</td>
<td>70</td>
<td>F</td>
<td>COPD</td>
<td>Prednisone 30 mg·day⁻¹ for 21 days</td>
<td>34.4</td>
<td>65</td>
<td>24</td>
</tr>
</tbody>
</table>

M: male; F: female; WBC: white blood cell count; PMNs: polymorphonuclear neutrophils; Lym: lymphocytes; ESR: erythrocyte sedimentation rate; HIV: human immunodeficiency virus; COPD: chronic obstructive pulmonary disease.

Table 2. – Sources of positive cultures, treatment and outcome

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Site of cultures</th>
<th>Treatment</th>
<th>Duration weeks</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>BAL, sputum</td>
<td>Imipenem</td>
<td>3</td>
<td>Localized (resolution)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TMP-SMX</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Sputum, abscess puncture</td>
<td>TMP-SMX</td>
<td>2</td>
<td>Dissemination to ST (death)</td>
</tr>
<tr>
<td>3</td>
<td>Pleural fluids, sputum</td>
<td>Ciprofloxacin</td>
<td>17</td>
<td>Localized (resolution)</td>
</tr>
<tr>
<td>4</td>
<td>Sputum, abscess puncture</td>
<td>TMP-SMX</td>
<td>26</td>
<td>Dissemination to ST (resolution)</td>
</tr>
<tr>
<td>5</td>
<td>Sputum</td>
<td>Amoxicillin-clavulanic acid</td>
<td>26</td>
<td>Localized (resolution)</td>
</tr>
<tr>
<td>6</td>
<td>Sputum, abscess puncture</td>
<td>TMP-SMX</td>
<td>2</td>
<td>Dissemination to CNS (death)</td>
</tr>
<tr>
<td>7</td>
<td>Sputum, BW</td>
<td>Netilmicin, ciprofloxacin</td>
<td>3</td>
<td>Localized (chronic infection)</td>
</tr>
<tr>
<td>8</td>
<td>Pleural fluid, pleural biopsy</td>
<td>Imipenem, TMP-SMX</td>
<td>3</td>
<td>Dissemination to ST (resolution)</td>
</tr>
<tr>
<td>9</td>
<td>Sputum, BAL, BW, urine</td>
<td>Ciprofloxacin</td>
<td>13</td>
<td>Dissemination to kidney (resolution)</td>
</tr>
<tr>
<td>10</td>
<td>Sputum, BAL, BW, BC</td>
<td>Imipenem</td>
<td>3</td>
<td>Localized (death)</td>
</tr>
</tbody>
</table>

TMP-SMX: trimethoprim-sulphamethoxazole; BAL: bronchoalveolar lavage; BW: bronchial washings; BC: brush catheter; CNS: central nervous system; ST: subcutaneous tissue.
Clinical outcome

Resolution of the disease was defined as eradication of Nocardia spp., together with clinical and radiological improvement. Pulmonary nocardiosis resolved in six patients (case Nos. 1, 3, 4, 5, 8 and 9), became chronic in one patient (case No. 7), and three patients died. The clinical end-points were freedom from fever, which was achieved during the first days (range 2–5 days) after treatment, with reduction in purulence of sputum and WBC counts. Radiological improvement lagged behind clinical parameters, with complete resolution in 1–3 months (patient Nos. 1, 3, 4, 8 and 9), and partial resolution in patient No. 5.

The disease was localized in five (case Nos. 1, 3, 5, 7 and 10) of the 10 patients (table 2). One of these patients (patient No. 7) showed previous pulmonary disease, with a trend towards chronicity. In this case, after initial improvement with appropriate antibiotic therapy and negative findings of Nocardia spp. in sputum cultures, recurrent infection appeared, as shown by identical antibiotic susceptibility studies for almost 2 yrs and, finally, after treatment with imipenem/amikacin, eradication was achieved. One patient with localized pulmonary nocardiosis (case No. 10) died because of a respiratory distress syndrome, in spite of proven in vitro sensitivity to antimicrobial therapy; this patient was receiving corticosteroid treatment. However, the other three (case Nos. 1, 3 and 5) showed radiographic resolution and microbiological eradication of Nocardia spp. at 3 months.

In five patients, pulmonary nocardiosis disseminated to subcutaneous tissue (patient Nos. 2, 4 and 8), to the central nervous system (patient No. 6) and to the kidney (patient No. 9). Two of these patients died at 1 and 2 months of evolution (patient Nos. 2 and 6); the former was receiving corticosteroid treatment. Patients with HIV infection evolved to resolution even though the disease had disseminated to subcutaneous tissue.

Two of the four patients receiving corticosteroid treatment died, whereas only one of the six not receiving corticosteroids died.

Antibiotic therapy was started empirically, with subsequent modification according to antibiotic sensitivity tests and clinical evolution. Patient Nos. 2, 4 and 6 were treated with trimethoprim-sulphamethoxazole (TMP/SMX), and, in spite of in vitro susceptibility, they developed a disseminated infection and two of them died. Patient Nos. 1, 8 and 10 received intravenous imipenem followed by oral TMP/SMX, with resolution at 2 months, and patient No. 10 died of respiratory distress syndrome.

**Discussion**

Nocardia species are common natural inhabitants of the soil throughout the world. Pulmonary nocardiosis is usually acquired by direct inhalation of Nocardia spp. from contaminated soil, and person-to-person transmission is rare. N. asteroides may be a saprophyte in the skin and in the upper respiratory tract. Respiratory colonization can occur, and in a compromised host it can progress to tissue invasion and dissemination [8, 9]. Roseff and Hodges [10] isolated Nocardia spp. from respiratory secretions in 36 patients, 19 of whom were free of disease. Most of those colonized had obstructive pulmonary disease. Host resistance to infection with Nocardia spp. is thought to depend on functioning phagocytic cells. Neutrophils limit spread of infection in the early stage of tissue invasion [11]. Activated macrophages and T-lymphocytes prevent dissemination and kill the bacteria [12]. The crucial role of cell-mediated immunity has been proved in experimental in vitro studies; thus, it is not surprising that Nocardia spp. behaves as an opportunist microorganism in an immunocompromised host [12, 13]. In the present study, we found underlying disease in 8 of the 10 cases of pulmonary nocardiosis: chronic obstructive pulmonary disease (COPD) (3), HIV infection (2), neoplastic disease (2) and alcoholism (1). Corticosteroid therapy was
associated in 40% of the cases. Several studies have shown that COPD is the disease most often treated with corticosteroid therapy [10, 13, 14]. Clinical features were similar to those in previous studies. Clinical findings were nonspecific, with a chronic course in 70% before diagnosis. Leucocytes were moderately raised, with a predominance of neutrophils.

Chest radiographic manifestations were pleomorphic, as described above. In the present study, consolidation was the most frequent finding (70%); masses appeared in 20%, with a predilection for upper lobes (70%). Feigin [15], in a review of 21 cases, described similar patterns and emphasized the presence of cavitation due to the necrotizing tendency of the abscesses and the association with obstructive pulmonary disease. In 21 patients with HIV infection, Kramer and Uttamchandani [16] observed the following radiographic findings: consolidation (52%), bilateral interstitial pattern (33%) and solitary mass (24%). Cavitation was associated in 62% of patients, and pleural effusion in 33%. The differential diagnosis of a solitary mass in an immunocompromised host must include pulmonary nocardiosis. In patients with acquired immune deficiency syndrome (AIDS) with superior bilateral infiltrates, pulmonary nocardiosis should be taken into account because, in AIDS patients, pulmonary tuberculosis does not normally show cavitation or upper lobe lesions. The diagnosis should always be based on isolation of Nocardia spp. in respiratory secretions. Sputum cultures were positive in 90% of the present patients, and in 100% when bronchoalveolar lavage was performed. The use of invasive diagnostic techniques improves the diagnostic yield; thus, these methods are justified when sputum fails to provide conclusive results. Isolation and identification of Nocardia spp. is troublesome. Nocardia spp. is a slowly growing microorganism that requires a prolonged period of incubation. Cultures should be maintained for at least 3 weeks before being discarded as negative. Nocardia asteroides was identified in 80% of cases. Recently, in a taxonomic revision, two new species were separated from Nocardia asteroides complex: Nocardia farcinica and Nocardia nova [1, 17]. Identification of these two new species can be achieved by gas chromatography, deoxyribonucleic acid (DNA) analysis and antimicrobial resistance patterns. Patient No. 7 showed the specific antimicrobial resistance pattern of N. farcinica. In 347 cases reported in the USA, N. asteroides was responsible for 85% of cases with pulmonary involvement [2]. Although N. brasiliensis usually causes cutaneous abscesses, it was shown that it can be implicated in pulmonary nocardiosis with identical clinical features [18].

The treatment of choice for this infection includes sulphonamides and, more recently, TMP-SMX, associated with surgical drainage when required [1]. However, failure with TMP-SMX has been reported, and we observed resistance in 2 out of 7 cases (29%). Most importantly, three patients treated with TMP-SMX that showed in vitro susceptibility developed a local spreading or disseminated infection, with a fatal outcome in two cases. Interpretation of antimicrobial testing of Nocardia spp. remains problematical [19]. Inoculum preparation, incubation of isolates and reading of inhibitory end-points may be difficult because of the characteristics of slow-er growth and tendency for elongation and branching. The NCCLS has recently organized a working group to standardize methods for susceptibility testing in the aerobic actinomycetes, including Nocardia spp.. The results of sensitivity testing do not always correlate with clinical outcome [20], so that this fatal evolution, together with the appearance of TMP-SMX-resistant Nocardia asteroides, provide a rational basis for considering combined therapy and alternative agents with a proven clinical response. It was observed that among these agents, netilmicin, amikacin and imipenem showed both in vitro susceptibility and clinical resolution [21]. Among the new β-lactams, cefmetazole has shown better in vitro susceptibility than imipenem [22]. Evidence from experimental studies using antimicrobial combinations has demonstrated synergy in vitro, which has also been supported by clinical observation with imipenem-amikacin, imipenem-ceftazidine and amikacin-ceftazidine [23, 24].

The duration of therapy required is unknown, but reports in the literature recommend 6 weeks in localized forms of nocardiosis and 6 months to 1 yr in disseminated nocardiosis [25–27]. In the present series, we observed resolution in six patients, three with localized and three with disseminated disease. Evolution in localized disease was normalization after 6 weeks of treatment. However, in patient No. 1, antibiotic treatment was prolonged due to his immunodepressed status. Dissemination appeared in the two patients with HIV infection and, surprisingly, in a patient without underlying disease. In spite of that, after 6 months of antibiotic treatment, Nocardia had been eradicated without subsequent recurrence. A trend towards chronicity was observed in one case (patient No. 7), with multiple recurrent episodes of infection, confirmed by identical antibiotic susceptibility studies. This peculiar case had a chronic pulmonary disease (bronchiectasis), and Nocardia that was resistant to TMP-SMX. The patient received successive treatments with aminoglycosides combined with imipenem or ciprofloxacins, and showed apparent cure with recurrences. Some authors have observed the persistence of L-forms within macrophages in vitro, but the relationship between this finding and recurrences of the disease has not been proved [28].

Evolution was fatal in three patients. Prognostic factors related to high mortality were associated with corticosteroid treatment and dissemination of the infection [4]. In the present series, mortality in the group of patients receiving corticosteroid treatment was high (2 out of 4), compared to the group not receiving such treatment (1 out of 6). Mortality has also been associated with dissemination, especially when the central nervous system is involved (80%) [3, 4], as was the case in the present series. However, the effect of corticosteroids and other possible factors, such as underlying disease or antibiotic therapy, did not appear to influence the local or systemic spread of the disease [3, 4]. A similar number of patients with or without corticosteroid treatment was found in localized and disseminated disease.

In summary, four general conclusions can be made. Firstly, pulmonary nocardiosis is difficult to diagnose on the basis of clinical and radiological findings. A high
level of clinical suspicion is required in patients with risk factors and in whom no other microorganisms have been identified. Microbiologists must be informed, in such cases, to include specific stains and cultures to investigate the presence of Nocardia spp. Secondly, species classically identified as Nocardia asteroides complex may contain five or more distinct groups, with major differences in their pathogenicity and invasive capabilities. Such variation may contribute to the broad clinical spectrum of pulmonary nocardiosis and also explain differences in response to therapy. Thirdly, susceptibility tests should be interpreted conservatively, taking into account that standardization is not achieved. Finally, difficulties in treatment arise due to the reasons discussed above. New alternative drug therapy and combined treatment with proven synergy, such as imipenem and amikacin, for initial therapy can offer some advantage, mainly in immunodepressed patients.

References